Recent studies indicate that resistant hypertension (RHTN) is present in about 12% of the treated hypertensive population. However, patients with true RHTN (confirmed out of the office) have not been widely studied. We prospectively studied 204 patients (123 male, 81female, mean age 48.4 years, range 19-65 years) with truly RHTN (ambulatory daytime mean blood pressure 4135/85 mm Hg). We evaluated the frequency of obstructive sleep apnea (OSA), renal artery stenosis (RAS), primary aldosteronism (PA) and other secondary forms of hypertension (HTN) and conditions. Mild, moderate and severe OSA were present in 55 (27.0%), 38 (18.6%) and 54 (26.5%) patients, respectively. Secondary forms of HTN were diagnosed in 49 patients (24.0%), the most frequent being PA (15.7%) and RAS (5.4%). Metabolic syndrome (MS) was present in 65.7% of patients. Excessive sodium excretion was evident in 33.3% of patients and depression in 36.8% patients. In patients with RHTN, OSA and MS were the most frequent conditions, frequently overlapping with each other and also with PA. Our data indicate that in the vast majority of patients with truly RHTN, at least one of three co-morbidities-OSA, MS and PA-is present. Other conditions, even though less frequent, should also be taken into the consideration.
INTRODUCTION
Resistant hypertension (RHTN) is defined as office blood pressure (BP) that remains above goal despite the concurrent use of three antihypertensive agents, in optimal doses, one of them being a diuretic. Recent studies indicate that RHTN is present in about 10-12% of the treated hypertensive population. [1] [2] [3] It has been shown that RHTN as compared with more easily controlled hypertension (HTN) is associated with more pronounced cardiovascular risk factor profile and worse prognosis. [4] [5] [6] Observational studies have enabled identification of those demographic and lifestyle characteristics associated with RHTN, and the role of secondary causes of HTN is well documented. 4 It should be noted that available studies are limited by the high cardiovascular risk and the presence of multiple co-morbid disease processes-including older age, diabetes and chronic kidney disease-which confound interpretation of the results.
However, patients with true RHTN have not been widely studied, particularly with regard to the systematic evaluation of those factors that are either associated with or which may promote resistance to antihypertensive treatment. Therefore, the aim of our study was to identify the clinical characteristics of patients with true RHTN and to evaluate the prevalence of factors known to contribute to treatment resistance-including obstructive sleep apnea (OSA), metabolic syndrome (MS) and secondary causes of HTN-and their relationship to BP profiles and the presence of target organ damage.
Subjects were required to meet predefined selection criteriatruly RHTN classified on the basis of ambulatory BP monitoring (ABPM) while staying on three antihypertensive drugs in optimal doses including diuretic. Also, as older age, diabetes and chronic kidney disease are strong risk factors for uncontrolled HTN, we included patients in the age range from 19 to 65 years, with preserved renal function (estimated glomerular filtration rate (eGFR) X60 ml min À 1 per 1.73 m 2 ) and without known history of diabetes.
MATERIALS AND METHODS Patients
Consecutive patients with RHTN referred to the Department of Hypertension, Institute of Cardiology, Warsaw, Poland, in the years 2009-2011, meeting pre-defined criteria and declaring good treatment adherence (as assessed by the referring doctor), were included into the RESIST-POL study. Inclusion criteria included: age between 19-65 years, truly RHTN (defined as clinic BP 4140/90 mm Hg and ambulatory daytime mean BP 4135/ 85 mm Hg while on three antihypertensive drugs in optimal doses including diuretic), preserved renal function (eGFR of X60 ml min À 1 per 1.73 m 2 ) and no history of diabetes. Patients with previously diagnosed OSA or secondary HTN were also excluded from the study. For all referred patients, ambulatory BP monitoring was repeated, to confirm the true RHTN and to obtain ABPM levels by one type of ABPM device. All before the confirmatory ABPM were interviewed again about the treatment adherence. As all patients were required to be treated with three antihypertensive drugs in optimal doses including diuretic no treatment modification were made at this stage of study.
Study procedure
The detailed clinical protocol included:(1) screening for coexisting conditions (OSA, impaired glucose metabolism, depression and excessive sodium excretion); (2) screening for secondary causes of HTN (primary aldosteronism (PA), renal artery stenosis (RAS), pheochromocytoma, Cushing syndrome (CS) and hyperthyroidism) and (3) evaluation of target organ damage in all patients. The study was approved by the Ethics Committee of the National Institute of Cardiology, Warsaw, and informed written consent was obtained from each patient.
Patient evaluation
All patients underwent standard clinical evaluation. Known duration of HTN was recorded. Weight and height as well as neck and waist circumferences were measured. Large neck circumference was defined as X41 cm orX43 cm for women and men respectively. 7 Body mass index (BMI) was calculated and obesity was considered as a BMI X30 kg m À 2 . Abdominal obesity was defined as waist circumference 4102 and 488 cm for women and men, respectively. 8 Current antihypertensive medications, current smoking, history of alcoholism, adrenergic medications and oral contraceptives were also documented.
Office BP measurements BP was measured by a trained nurse with a patient in the sitting position after a 5-min rest, using an automated device (Omron 705IT, Omron Co., Kyoto, Japan). Based on upper arm circumference an appropriately sized cuff was placed on the arm with the lower edge of the cuff 2 cm above the antecubital fossa. Three consecutive readings were performed. If the difference between readings was higher than 10 mm Hg, further measurements were taken so as to obtain three consecutive consistent readings. The average of these three readings was recorded.
Ambulatory BP measurements
In all patients, ambulatory BP measurements were recorded using SpaceLabs 90207 or 90217 (Redmond, WA, USA). Based on upper arm circumference measurement appropriately sized cuff was used. Readings were obtained every 15 min during the day (0600-2200 hours) and every 30 min during the night (2200-0600 hours). Differentiation between sleep and activity periods was made after recoding based on data from the patient diary. Nocturnal decrease in BP was quantified as the relative decrease in nocturnal BP for both systolic and diastolic BP: [(daytime pressure-nighttime pressure)/daytime pressure] Â 100 and expressed as a percentage. Subjects were classified as dippers if the proportional decrease from awake to asleep BP was X10%.
Laboratory methods
Biochemical evaluation of blood samples taken after overnight fasting were determined by routine methods, and included sodium and potassium, lipids, blood count, fasting plasma glucose (FPG), creatinine and uric acid. An oral glucose tolerance test was performed with a 75-g glucose load to evaluate plasma glucose level 2 h after glucose administration (2hPG). eGFR was calculated using the Modification of Diet in Renal Disease formula. 9 Albuminuria, aldosterone and sodium excretion were assessed using a 24-h urine collection. Excessive sodium ingestion was defined as 24 h sodium excretion 4200 mEq per 24 h. 10 Microalbuminuria was defined as 24 h albumin excretion 430 mg and o300 mg per 24 h. Glucose and lipid metabolism abnormalities were diagnosed on the basis of the 2007 European Society of Hypertension/ European Society of Cardiology (ESH/ESC) guidelines-normal FPG: o5.6 mmol l À 1 and impaired FPG: 5.6-6.9 mmol l À 1 ; abnormal glucose tolerance was diagnosed if 2hPG was 7.8-11.0 mmol l À 1 ; diabetes was diagnosed if two measures of FPG were X7.0 mmol l À 1 or 2hPG 411.0 mmol l À 1 . 8 For diagnosis of MS, three of five criteria had to be met: (1) BP X130/X85 mm Hg-this criterion was met for all patients; (2) abdominal obesity-waist circumference of male 4102 cm, female 488 cm; (3) [11] [12] [13] To screen for PA, the plasma aldosterone-to-renin ratio was evaluated in all patients. To confirm the diagnosis of PA, further testing was performed in patients with increased aldosterone-to-renin ratio (430) and serum aldosterone concentration (415 ng dl À 1 ). As current guidelines suggest that the saline infusion test should not be performed in patients with severe uncontrolled HTN, 12 the captopril challenge test was conducted to confirm the diagnosis of PA, which was made in patients showing failure of aldosterone to suppress more than 30%. Medication treatment was tailored (after other examination were performed) according to current guidelines, including withdrawing spironolactone, diuretics and other drugs when appropriate before evaluations. 12 A diagnosis of pheochromocytoma was based on metanephrine excretion in the urine, and diagnosis of CS was based on the 1-mg overnight dexamethasone suppression test, which was performed in all patients. 13 Screening for hyperthyroidism was conducted using thyroidstimulating hormone (TSH) levels; in patients with abnormal TSH, further diagnosis included evaluation of free T4 and free T3 levels.
Echocardiography
Standard transthoracic echocardiographic studies were performed with the GE Vivid 7 using a 2.5-3.5 MH transducer. The left ventricle mass was calculated using the modified American Society of Echocardiography cube formula proposed by Devereux et al.
14 and was indexed to body surface area to obtain the left ventricle mass index. Left ventricular hypertrophy was defined according to the ESH/ESC 2007 criteria. 8 
Doppler duplex ultrasonography
Ultrasonography examination and duplex Doppler imaging were performed with a Philips HD11 scanner (Philips, Eindhoven, the Netherlands) with 2-4 MHz phased-array transducer. Patients were scanned in the supine position while in the fasting state. To estimate RAS, the renal aortic ratio was calculated as the ratio of renal artery to aorta maximal peak systolic velocities. Renal aortic ratio 43-3.5 and peak systolic velocity 42 m s À 1 in renal artery have been used as a criteria for significant RAS. 15 
Spiral computed tomography
Computed tomography (CT) examinations of renal arteries, kidneys and adrenal glands were performed with a 64-detector CT scanner (Somatom DEFINITION; Siemens, Erlangen, Germany) in all patients. Scanning parameters were 0.6-mm collimation, slices thickness 1 mm, pitch of 1, 0.33-s gantry rotation, 120 kV, 100-160 mAs. The angio-CT examination of renal arteries was performed after the intravenous injection of 100 ml bolus 350-370 mg ml À 1 of nonionic iodinated contrast medium administered at a rate of 5 ml s À 1 . Image acquisition was initiated after 4-5 s when the threshold enhancement of 100 HU was reached within the region of interest placed on the descending aorta. Significant RAS was defined as the narrowing of the artery diameter of at least 60% in comparison with the diameter of intact artery (excluding post-stenosis dilation) in a multiplanar reconstructions. 15 The final diagnosis of RAS was based on angio-CT results. Those patients with an adrenal mass that had attenuation values greater than 10 HU at unenhanced imaging underwent additional enhanced CT imaging 60 s and 15 min (delayed CT) after intravenous administration of contrast material. Mean percentage of enhancement washout was calculated.
Polysomnography
The Epworth Sleepiness Scale was evaluated before the sleep study. In all patients, data regarding mean sleep duration time and snoring were also assessed. All patients irrespectively of symptoms of OSA were evaluated by standard attended polysomnography with an Alice 5 (Respironics Inc., Murrysville, PA, USA) device. The polysomnographic recordings were scored manually using 30-s epochs following Rechtschaffen and Kales' criteria for sleep and wake determination and sleep staging. 16 Abnormal respiratory events were evaluated according to standard criteria of the American Academy of Sleep Medicine Task Force. 17 
RESULTS
A total of 256 consecutive patients referred to the Department of Hypertension, Institute of Cardiology, Warsaw, Poland, meeting pre-defined criteria were initially evaluated. From that group 52 patients were excluded (Supplementary Figure 1) , so that the final analysis included 204 patients (123 male, 81 female, mean age 48.4 years, range 19-65 years). The population studied was middle-aged, with a high prevalence of abdominal obesity (73%) as well as of obesity defined by BMI of 30 kg m À 2 or more (47.5%) and a majority of them are men (Table 1) . Median number of antihypertensive drugs was four and individual antihypertensive medication drug classes were prescribed with the following frequencies: thiazide/loop diuretics 97.5%, calcium channel blockers 86.3%, b-blockers 79.4%, angiotensin-converting-enzyme inhibitors (ACEIs) 67.2%, angiotenin receptor blockers (ARBs) 55.9%, a-blockers 43.6%, centrally acting drugs 13.2% and spironolactone 10.8% (no patient was receiving eplerenone). Fixed dose combination drugs were prescribed in 12.3% of patients and all patients took thiazide/loop diuretic and/or spironolactone.
The frequency of associated conditions and secondary causes of HTN is summarized in Figure 1 . The most common associated condition was OSA, which was diagnosed in 147 patients (72.1%). Mild, moderate and severe OSA occurred, respectively, in 55 (27.0%), 38 (18.6%) and 54 (26.5%) patients. Secondary forms of HTN were diagnosed in 49 patients (24.0%); the most frequent was PA in 32 patients (15.7%). RAS was diagnosed in 11 patients (5.4%), CS in 2 patients (1.0%), hyperthyroidism was found in 3 patients (1.5%) and in 1 patient renal artery aneurysm was diagnosed. MS was diagnosed in 134 patients (65.7%). On oral glucose tolerance test, previously undiagnosed diabetes was found in 29 (14.2%) patients, excessive sodium excretion was noted in 68 (33.3%) patients and depressive symptoms in 75 (36.8%) patients. None of these comorbidities was evident in only 9 patients (4.4%), one in 28 subjects (13.7%), two in 72 subjects (35.3%) and three or more in 95 patients (46.6%).
As compared with patients without OSA, patients with OSA were characterized by older age, longer known duration of HTN and a male predominance (Table 1) . Patients with OSA also exhibited several metabolic abnormalities and were characterized by higher indices of obesity, including BMI (55.8% vs 26.3%; Po0.001), and a higher likelihood of increased neck circumference (47.2% vs 19.6%; Po0.001). There were no differences between patients with OSA and without OSA in number of antihypertensive medications, ambulatory BP levels, nocturnal BP decline or frequency of LVH and microalbuminuria, nor in frequency of reported snoring and Epworth Sleepines Score (Tables 1 and 2 ). There was a weak but significant correlation between aldosterone Characteristics
with secondary HTN were excluded, the correlation remained significant (r ¼ 0.24; P ¼ 0.009). It was still significant when controlled for 24-h sodium excretion. In patients without secondary HTN, serum concentration of aldosterone and AHI were significantly correlated (r ¼ 0.17; P ¼ 0.032). In a multivariate analysis, male sex, age and abdominal obesity were independently associated with the presence of OSA (Table 3) . Further analysis was conducted to assess the impact of OSA severity on clinical variables ( Supplementary Tables 1 and 2 ). All evaluated variables showed relationships with increasing OSA severity, except known duration of HTN, eGFR level, and clinic and ambulatory BP levels. The most pronounced differences were noted between patients without OSA and patients with severe OSA. In a multivariate analysis, male sex, abdominal obesity and 2hPG X140 mg dl À 1 were independently associated with the presence of severe OSA (Supplementary Table 3 ).
The most frequent MS components were abdominal obesity (73.8%), followed by increased fasting glucose or diabetes (53.9%), decreased high-density lipoprotein cholesterol (47.0%) and increased triglycerides (45.5%). Only in a minority of 73 patients (35.8%), there was no glucose metabolism abnormalities detected. Patients with MS were older age (49.8±9.6 vs 45.9±12.0 years; Increased aldosterone-to-renin ratio and serum aldosterone concentrations were present in 58 patients (28.4%) and the diagnosis of PA was further confirmed in 32 patients (15.7%). Patients with PA had lower potassium levels and higher sodium levels, as compared with patients without secondary causes of HTN ( Table 4 ). The frequency of serum potassium levels o4.0 and o3.5 mEq l À 1 was strikingly higher in patients with PA as compared with patients without secondary causes of HTN (64.5% vs 18.3%; Po0.001 and 22.6% vs 2.0%; Po0.001, respectively). Patients with PA were also characterized by higher systolic clinic, systolic daytime and both systolic and diastolic nighttime BP levels as well as by less pronounced nocturnal fall of systolic and diastolic BP (Table 2 ) and a higher frequency of nondipping diastolic BP (54.8% vs 33.3%; P ¼ 0.023). It should be noted that patients with PA were also characterized by a higher frequency of impaired glucose tolerance and newly diagnosed diabetes (Table 4) . OSA, MS or comorbid OSA and MS occurred, respectively, in 78.1%, 78.1% and 68.7% of patients with PA ( Figure 2 ). The frequencies of LVH and microalbuminuria were also higher in patients with PA as compared with patients without secondary causes of HTN. In multivariate analysis, serum potassium of less than 4.0 mmol l À 1 , higher nighttime systolic BP, 2hPG X140 mg dl À 1 and microalbuminuria were independently related with the presence of PA (Table 5) .
Significant RAS was diagnosed in 11 patients (in 8 patients significant RAS was present both on duplex Doppler examination and angio-CT, in 3 patients only angio-CT revealed significant RAS). In one patient, angio-CT did not confirm significant RAS, which was suspected based on duplex Doppler examination. In three male patients (mean age 36.7 years), RAS was caused by fibromuscular dysplasia. In the other eight patients (three male, five female, mean age 56.0 years), atherosclerotic RAS was found. Except for higher nighttime systolic BP, no differences in other 
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clinical variables were noted in patients with significant RAS vs those without secondary causes of HTN (Tables 2 and 4) .
Depressive symptoms were reported more frequently by women than men (50.6% vs 27.6%; Po0.001). Patients with depressive symptoms as compared with patients without were characterized by higher daytime and 24 h heart rate (74 ± 12 vs 70±10 min À 1 ; P ¼ 0.046 and 70±11 vs 66±10 min À 1 ; Po0.05, respectively), higher office systolic BP (165 ± 23 vs 158 ± 20 mm Hg; P ¼ 0.033) and higher differences between office and daytime systolic BP levels (21±20 vs 12±19 mm Hg; P ¼ 0.003). There were no differences in age and ABPM BP levels between patients with and without depressive symptoms, nor in the frequency of LVH, microalbuminuria or other clinical characteristics.
DISCUSSION
Our study systematically evaluated 204 patients with true RHTN, which to our knowledge, is the largest sample of patients with RHTN confirmed by ABPM, to be studied. For the purposes of our study, we included middle-aged patients with preserved renal function and without known history of diabetes, as cross-sectional studies have thus far shown that increasing age, renal dysfunction and diabetes are strongly associated with antihypertensive drug resistance. 4, 19 One of our most important findings is the high prevalence of OSA (72.1%) in truly RHTN, in keeping with data from previous clinical studies. 20 However, in only two prior studies was treatment resistance confirmed by ABPM, and most prior studies consisted of relatively modest sample sizes. 20 Based on the large number of patients with true RHTN, we comprehensively phenotyped patients with OSA and RHTN, including BP profile, metabolic abnormalities and the presence of PA, allowing the novel identification of characteristics and comorbidities of RHTN patients with and without OSA.
Our study showed that patients with RHTN with coexisting OSA were older, more often male, had higher BMI, higher prevalence of abdominal obesity, impaired glucose metabolism and were more likely to have the MS. Moreover, the most pronounced metabolic abnormalities were present in those patients with severe OSA. In the recent study by Pedrosa et al., 21 which included patients with true RHTN, BMI and the presence of MS were also higher among patients with OSA than in subjects without OSA. Our study adds the important finding that abdominal obesity and impaired glucose tolerance were independently related to the presence of OSA in RHTN. It should be also noted that in a multivariate model, abdominal obesity, but not obesity defined by BMI, was independently related to the presence of OSA and severe OSA further supporting the concept that BMI has a low sensitivity to identify adiposity. 22 The mechanisms responsible for the high incidence of OSA among patients with RHTN are complex and not fully elucidated. 
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Recent data suggest that OSA is associated with the same cardiovascular risk factors that characterize RHTN, including obesity, impaired glucose tolerance and dyslipidemia. It is possible that OSA either directly increases these risk factors, or that OSA and RHTN share common risk factors, particularly obesity. 23, 24 Alternatively, the presence of OSA in hypertensive patients may contribute to further BP elevation, leading to a RHTN profile, however, in our study, even the severe OSA was not related with higher BP levels. Recent studies showed that in contrast to patients with controlled HTN, those with RHTN have a higher AHI that was proportional to a more pronounced fluid volume displacement from the legs to the neck during the night. Such overnight rostral fluid shifts may have a role in the development of upper airway obstruction during sleep. 25 It has been also suggested that hyperaldosteronism may contribute importantly to worsening the clinical course of OSA in patients with RHTN 20 and that the positive correlation between plasma and 24-h urinary aldosterone levels and AHI in patients with RHTN is largely attributable to patients with hyperaldosteronism. 26 In our study, we found a high proportion of OSA in patients with PA, and also a positive correlation between plasma and 24-h urinary aldosterone levels. Importantly, our study showed an overlapping of MS, OSA and PA what suggests a common pathophysiologic substrate and/or phenotype, related to RHTN. 20, 24 The frequent comorbidity of OSA and PA in patients with RHTN provide also support for the concept of salt and water retentionpromoting fluid accumulation in the neck, predisposing to OSA. 
The high prevalence of excessive sodium intake, in a third of our subjects, speaks further for salt and water retention as potential mechanism contributing to OSA in RHTN.
The non-dipping pattern of BP during the night has been reported as a feature of patients with OSA. 20, 27 However, in our large sample size patients with RHTN, values of 24-h ambulatory BP and nocturnal dipping pattern did not differ between patients with OSA as compared with those without OSA, findings also evident in another recent study, which showed no association between higher ambulatory BP levels nor nocturnal dipping pattern and the presence of OSA in patients with RHTN. 21 Although antihypertensive medications may attenuate nondipping, an important clinical implication of our data is that a normal dipping pattern does not exclude OSA in patients with true RHTN.
It has been reported that excessive daytime sleepiness could be a marker of a pathogenic mechanism linking OSA with HTN, and in contrast to AHI, only the Epworth Sleepiness Scale score was associated with 24-h diastolic BP. 28 Another novel observation in our study is that in patients with true RHTN and OSA, the Epworth Sleepiness Scale levels were relatively low and were not a predictor of OSA, except in those patients with severe OSA. This may partially explain why, despite the growing awareness of OSA, most patients remain undiagnosed.
Our results, showing high prevalence of OSA but no clear association between OSA and BP levels in RTHN patients, may rise concern whether OSA should be screened in all RHTN patients. It may be argued that such approach should be limited to symptomatic patients who may benefit from the therapy. However, it should be stressed that there is evidence from observational and nonrandomized trial data suggesting that treatment of OSA has the potential to prevent fatal and nonfatal cardiovascular events, suggesting benefits of OSA screening and treatment in both symptomatic and asymptomatic patients. 27, 29 Data from our and other studies indicate that RHTN patients have a relatively high prevalence of PA, the presence of which relates to the severity of HTN. 30 In our study, the incidence of PA (15.7%) was similar to most of the prospective studies reported so far describing a prevalence of 14-21%. 4, 30 It should be noted that in our study the less frequently used captopril suppression test was used. Captopril suppression test has been reported to be less accurate than saline infusion test in patients with lower sodium intake. 31 However, it was not possible to use the saline infusion test in all patients as it may carry a substantial risk in patients with severe uncontrolled HTN. 12 Because we wanted to use only one confirmatory test in all patients, we decided to resort to the captopril suppression test for all patients as there are no absolute contraindications to this test.
Our additional novel findings relate to clinical characteristics of patients with PA and RHTN. Patients with PA were characterized by higher systolic daytime and nighttime BP and higher number of antihypertensive drugs taken. In previous studies in RHTN patients, inconsistent results with regard to office BP in patients with PA were reported and no study used ABPM. [32] [33] [34] Multivariate logistic regression identified lower plasma potassium, higher nighttime BP, the presence of microalbuminuria and impaired glucose tolerance as predictors of PA among patients with true RHTN. The high prevalence of abnormalities in glucose metabolism and target organ damage in patients with PA may contribute to the high cardiovascular risk of patients with PA, reported in recent studies. 35 RAS is regarded as common among patients with RHTN; however, there has been no robust prior study in patients with RHTN assessing the presence of RAS. 36 Our data showed that the prevalence of RAS was 5.4% and was slightly higher than that recently reported by Pedrosa et al., 21 in a report of 124 consecutive patients with true RHTN screened by means of Doppler duplex. It is difficult to compare both groups as in our study we excluded those with impaired renal function, and thus may underestimate the number of patients with RAS. An important and novel strength of the prevalence data we report is that angio-CT of renal arteries was performed in all patients with true RHTN.
We also noted a relatively high prevalence of depressive symptoms (36.8%) in patients with RHTN. It is of interest that patients with depression were characterized by higher daytime heart rate and higher differences between office and ambulatory BP levels, suggesting a more pronounced white coat effect in patients with depression. In our study, depression was reported more frequently by women than men, and there were no differences in age and ABPM levels between patients with and without depression. The presence of depressive symptoms in patients with RHTN is of considerable clinical relevance as depression might be related to poor adherence to antihypertensive medications. 37 Our study has a number of important strengths. First, it is the largest prospective, systematic evaluation of patients with true RHTN in relation to the presence of concomitant diseases and secondary causes related with treatment resistance; second, we conducted a comprehensive and robust investigation of multiple comorbidities and risk factors in all subject including evaluation of clinical characteristics of patients with RHTN associated with OSA, PA and MS; and third, we included only middle aged or younger subjects with preserved renal function and without a history of diabetes, thus mitigating the potential confounding effects of advanced age and comorbidities on our results. Therefore, our results may not be applicable to the broader population of patients with truly RHTN. It should be noted that in several studies both diabetes and chronic kidney disease were independently linked with RHTN. 38, 39 We conclude that patients with true RHTN have very high prevalences of OSA (72%) and MS (66%), frequently coexisting with each other and also with PA. This may suggest a common pathological phenotype related to RHTN, or a common etiologic substrate. We also note that OSA in the setting of RHTN is not accompanied by higher daytime and nighttime BP levels nor by nocturnal non-dipping of BP. Our data suggest that evaluating and treating RHTN according to these clinical characteristics and comorbidities, may contribute importantly not only to BP control, but also to improving overall cardiovascular outcomes in this patient population.
What is known about the topic
Resistant hypertension is present in about 12% of the treated hypertensive population. Patients with truely resistant hypertension (confirmed out of the office) have not been widely studied, particularly with regard to the systematic evaluation of those factors which are either associated with or which may promote treatment resistance in one group of patients.
What this study adds
It is the largest prospective, systematic evaluation of patients with true resistant hypertension in relation to the presence of concomitant diseases and secondary causes related with treatment resistance. In patients with true resistant hypertension, there is an important overlapping of metabolic syndrome, obstructive sleep apnea and primary aldosteronism, which are frequent. In patients with resistant hypertension, abdominal obesity, but not blood pressure levels and profile nor excessive sleepiness, was related with the presence of obstructive sleep apnea. 
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